Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Pediatric Evolutionary Tumor Board (pedsETB), is exploring new treatment options for children and young adults with cancer who may not have effective standard treatments available. The focus is on patients who are considered likely incurable, which includes those who have just been diagnosed, have relapsed, are in remission but at high risk of their cancer returning, or have not responded well to previous therapies. The goal is to see if a team of experts from different medical fields can come together to develop better therapeutic strategies for these patients.

To participate, patients must meet specific criteria. They should have a performance level indicating they can tolerate treatments (for example, being able to walk and take care of themselves) and be open to considering new treatment recommendations from the pedsETB team. Participants will be asked to agree to allow their medical data to be collected over time, which could include scans and blood samples. It's important for participants and their guardians to understand the trial and give their consent before joining. Overall, this trial aims to offer hope and potentially better outcomes for young patients facing tough cancer battles.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care.
• • The site investigator will make this determination based on their experience.
• • Participant must have an age-appropriate performance status: Karnofsky 50 or more for patients 16 years of age or older OR Lansky score of 50 or more for patients less than16 years of age.
• • Participant and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB.
• • Participant must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling.
• • All Participants and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.
• Exclusion Criteria:
• • Participants without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.